{"id":"W2140338938","doi":"10.1158/1078-0432.ccr-05-0262","title":"Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Adverse effect; Response Evaluation Criteria in Solid Tumors; Asymptomatic; Cancer; Metastasis; Pathology; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005272778,0.001163216,0.001268065,0.0003462325,0.0002926797,0.0005801904,0.0005213331,0.0008221528,0.002489274],"category_scores_gemma":[0.0003932099,0.0003835462,0.000666559,0.0003265338,0.0005658066,0.0004186406,0.0002345964,0.002050665,0.0004464673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000623944,"about_ca_system_score_gemma":0.0006832956,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007211129,"about_ca_topic_score_gemma":0.001672006,"domain_scores_codex":[0.9998486,0.00005557898,0.000007345789,0.0000305572,0.00001683117,0.00004109275],"domain_scores_gemma":[0.9997581,0.00003666976,0.00006369391,0.00002139675,0.00001525027,0.0001049319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3619487,0.07167452,0.01350713,0.0009978014,0.001260149,0.0006004909,0.0005151793,0.009351443,0.3164768,0.0009748297,0.00772092,0.2149719],"study_design_scores_gemma":[0.212951,0.7304566,0.0220853,0.00005181846,0.0005117233,0.0006059316,0.0000797348,0.00313415,0.02323288,0.0003438047,0.006510845,0.00003618416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914204,0.002664589,0.0007942689,0.000278552,0.00006390514,0.001577471,0.0006142518,0.0001165786,0.002469978],"genre_scores_gemma":[0.9910998,0.001872221,0.00163459,0.0004662639,0.00009579591,0.001351392,0.001386671,0.00002312549,0.002070105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002489274,"threshold_uncertainty_score":0.008327425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1781517426797625,"score_gpt":0.588530311715438,"score_spread":0.4103785690356755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}